Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1992 1
1994 1
1996 1
1999 6
2000 3
2001 3
2002 8
2003 5
2004 4
2005 6
2006 4
2007 6
2008 4
2009 4
2010 10
2011 4
2012 7
2013 11
2014 7
2015 9
2016 6
2017 7
2018 9
2019 10
2020 6
Text availability
Article attribute
Article type
Publication date

Search Results

132 results
Results by year
Filters applied: . Clear all
Page 1
Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management.
Eaton JE, Talwalkar JA, Lazaridis KN, Gores GJ, Lindor KD. Eaton JE, et al. Gastroenterology. 2013 Sep;145(3):521-36. doi: 10.1053/j.gastro.2013.06.052. Epub 2013 Jul 1. Gastroenterology. 2013. PMID: 23827861 Free PMC article. Review.
Primary sclerosing cholangitis (PSC), first described in the mid-1850s, is a complex liver disease that is heterogeneous in its presentation. ...
Primary sclerosing cholangitis (PSC), first described in the mid-1850s, is a complex liver disease that is heterogeneou
Pathogenesis and clinical spectrum of primary sclerosing cholangitis.
Gidwaney NG, Pawa S, Das KM. Gidwaney NG, et al. World J Gastroenterol. 2017 Apr 14;23(14):2459-2469. doi: 10.3748/wjg.v23.i14.2459. World J Gastroenterol. 2017. PMID: 28465630 Free PMC article. Review.
Primary sclerosing cholangitis (PSC) is a disease of the biliary tract, which has been documented in the literature since 1867. ...Many new treatment modalities have emerged in the recent past, including anti-tumor necrosis factor- α and
Primary sclerosing cholangitis (PSC) is a disease of the biliary tract, which has been documented in the literature sin
Colorectal Cancer in Inflammatory Bowel Disease.
Stidham RW, Higgins PDR. Stidham RW, et al. Clin Colon Rectal Surg. 2018 May;31(3):168-178. doi: 10.1055/s-0037-1602237. Epub 2018 Apr 1. Clin Colon Rectal Surg. 2018. PMID: 29720903 Free PMC article. Review.
Risk factors that further increase the risk of IBD-related CRC include disease duration, extent and severity, the presence of inflammatory pseudopolyps, coexistent primary sclerosing cholangitis, and a family history of CRC. ...Finally, the expanding armament …
Risk factors that further increase the risk of IBD-related CRC include disease duration, extent and severity, the presence of inflammatory p …
Molecular Pathogenesis of Cholangiocarcinoma.
Labib PL, Goodchild G, Pereira SP. Labib PL, et al. BMC Cancer. 2019 Feb 28;19(1):185. doi: 10.1186/s12885-019-5391-0. BMC Cancer. 2019. PMID: 30819129 Free PMC article. Review.
RISK FACTORS FOR CHOLANGIOCARCINOGENESIS: Cholestatic liver diseases (e.g. primary sclerosing cholangitis and fibropolycystic liver diseases), liver cirrhosis, and biliary stone disease all increase the risk of cholangiocarcinoma. ...Chronic inflammation lead …
RISK FACTORS FOR CHOLANGIOCARCINOGENESIS: Cholestatic liver diseases (e.g. primary sclerosing cholangitis and fibropoly …
Extraintestinal Manifestations in Vedolizumab and Anti-TNF-Treated Patients With Inflammatory Bowel Disease.
Dubinsky MC, Cross RK, Sandborn WJ, Long M, Song X, Shi N, Ding Y, Eichner S, Pappalardo B, Ganguli A, Wang A. Dubinsky MC, et al. Inflamm Bowel Dis. 2018 Aug 16;24(9):1876-1882. doi: 10.1093/ibd/izy065. Inflamm Bowel Dis. 2018. PMID: 29668916
This study compared incidence rates of EIMs in patients with moderate to severe IBD receiving gut-selective vedolizumab (VDZ) vs those receiving systemic anti-tumor necrosis factor (anti-TNF) therapies. ...Specifically, CD patients treated with VDZ were more …
This study compared incidence rates of EIMs in patients with moderate to severe IBD receiving gut-selective vedolizumab (VDZ) vs those recei …
Extraintestinal Manifestations of Inflammatory Bowel Disease.
Vavricka SR, Schoepfer A, Scharl M, Lakatos PL, Navarini A, Rogler G. Vavricka SR, et al. Inflamm Bowel Dis. 2015 Aug;21(8):1982-92. doi: 10.1097/MIB.0000000000000392. Inflamm Bowel Dis. 2015. PMID: 26154136 Free PMC article. Review.
For other not so rare EIM, such as pyoderma gangrenosum and primary sclerosing cholangitis, the association with the activity of the underlying IBD is unclear. ...Besides other options, tumor necrosis factor antibody therapy is an importa …
For other not so rare EIM, such as pyoderma gangrenosum and primary sclerosing cholangitis, the association with the ac …
Vedolizumab Treatment in Extra-Intestinal Manifestations in Inflammatory Bowel Disease: A Systematic Review.
Chateau T, Bonovas S, Le Berre C, Mathieu N, Danese S, Peyrin-Biroulet L. Chateau T, et al. J Crohns Colitis. 2019 Dec 10;13(12):1569-1577. doi: 10.1093/ecco-jcc/jjz095. J Crohns Colitis. 2019. PMID: 31076751
Vedolizumab did not show any effectiveness in primary sclerosing cholangitis [PSC]. While no effect was seen in pre-existing manifestations regarding arthralgia and arthritis, the occurrence of new rheumatic symptoms was lower among vedolizumab users compared …
Vedolizumab did not show any effectiveness in primary sclerosing cholangitis [PSC]. While no effect was seen in pre-exi …
Bile-Derived Organoids From Patients With Primary Sclerosing Cholangitis Recapitulate Their Inflammatory Immune Profile.
Soroka CJ, Assis DN, Alrabadi LS, Roberts S, Cusack L, Jaffe AB, Boyer JL. Soroka CJ, et al. Hepatology. 2019 Sep;70(3):871-882. doi: 10.1002/hep.30470. Epub 2019 Mar 13. Hepatology. 2019. PMID: 30561836
Primary sclerosing cholangitis (PSC) is a heterogeneous and progressive fibroinflammatory cholangiopathy with no known etiology or effective treatment. ...Incubation of these BDOs with interleukin 17A or tumor necrosis factor alpha
Primary sclerosing cholangitis (PSC) is a heterogeneous and progressive fibroinflammatory cholangiopathy with no known
Extraintestinal Manifestations of Pediatric Inflammatory Bowel Disease: Prevalence, Presentation, and Anti-TNF Treatment.
Greuter T, Bertoldo F, Rechner R, Straumann A, Biedermann L, Zeitz J, Misselwitz B, Scharl M, Rogler G, Safroneeva E, Ali RAR, Braegger C, Heyland K, Mueller P, Nydegger A, Petit LM, Schibli S, Furlano RI, Spalinger J, Schäppi M, Zamora S, Froehlich F, Herzog D, Schoepfer AM, Vavricka SR; Swiss IBD Cohort Study Group. Greuter T, et al. J Pediatr Gastroenterol Nutr. 2017 Aug;65(2):200-206. doi: 10.1097/MPG.0000000000001455. J Pediatr Gastroenterol Nutr. 2017. PMID: 27801751 Free article.
Thirty-one of the 55 patients (56.4%) were treated with 1 or more anti-tumor necrosis factor (TNF) agents. IBD patients with EIM were more likely to be treated with anti-TNF compared to those without (56.4% vs 35.0%, P = 0.003). ...
Thirty-one of the 55 patients (56.4%) were treated with 1 or more anti-tumor necrosis factor (TNF) agents. IBD patients …
Inflammatory Bowel Disease Types Differ in Markers of Inflammation, Gut Barrier and in Specific Anti-Bacterial Response.
Coufal S, Galanova N, Bajer L, Gajdarova Z, Schierova D, Jiraskova Zakostelska Z, Kostovcikova K, Jackova Z, Stehlikova Z, Drastich P, Tlaskalova-Hogenova H, Kverka M. Coufal S, et al. Cells. 2019 Jul 13;8(7):719. doi: 10.3390/cells8070719. Cells. 2019. PMID: 31337064 Free PMC article.
Crohn's disease (CD), ulcerative colitis (UC) and inflammatory bowel disease (IBD) associated with primary sclerosing cholangitis (PSC-IBD), share three major pathogenetic mechanisms of inflammatory bowel disease (IBD)-gut dysbiosis, gut barrier failure and i …
Crohn's disease (CD), ulcerative colitis (UC) and inflammatory bowel disease (IBD) associated with primary sclerosing chola
132 results
Jump to page
Feedback